TRI AZULIX 2 DS 10S

About

TRI AZULIX 2 DS is a triple-combination oral antidiabetic medication designed for comprehensive management of type 2 diabetes mellitus. It typically combines Glimepiride (a sulfonylurea), Metformin (a biguanide), and Pioglitazone (a thiazolidinedione). Glimepiride stimulates insulin secretion from pancreatic beta cells, Metformin reduces hepatic glucose production and improves insulin sensitivity, while Pioglitazone enhances insulin sensitivity in peripheral tissues and the liver. This multi-pronged approach targets different pathophysiological defects of type 2 diabetes, leading to robust glycemic control, especially in patients inadequately controlled by dual therapy.

This combination aims to achieve sustained blood glucose reduction, improve insulin utilization, and manage various aspects of diabetes pathology. It is used as an adjunct to diet and exercise when monotherapy or dual therapy fails to provide adequate glycemic control.

Uses

• Management of type 2 diabetes mellitus
• Improved glycemic control
• When dual therapy is insufficient
• Adjunct to diet and exercise

Directions For Use

Take orally, usually once or twice daily with meals, as directed by your healthcare provider.

Benefits

• Comprehensive blood sugar control
• Targets multiple diabetes pathways
• Improved insulin sensitivity
• Reduced hepatic glucose output
• Sustained glycemic reduction
• Potential for significant A1c lowering

Side Effects

• Hypoglycemia (due to glimepiride)
• Nausea, vomiting, diarrhea
• Abdominal pain, metallic taste
• Weight gain, fluid retention, edema
• Heart failure (rare, due to pioglitazone)
• Lactic acidosis (rare, due to metformin)
• Bladder cancer risk (rare, due to pioglitazone)
• Bone fractures (rare, due to pioglitazone)
• Headache
• Dizziness
• Upper respiratory tract infection
• Vitamin B12 deficiency (long-term metformin use)

Safety Measures

• Alcohol - Avoid excessive alcohol consumption due to an increased risk of hypoglycemia (glimepiride) and lactic acidosis (metformin).
• Pregnancy - Not recommended during pregnancy. Insulin is generally preferred for glycemic control in pregnant women. Consult your doctor.
• Breastfeeding - Not recommended during breastfeeding as components may pass into breast milk. Consult your doctor.
• Liver - Contraindicated in severe hepatic impairment due to the metformin and pioglitazone components. Regular monitoring of liver function is essential.
• Kidney - Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73m²) due to the risk of metformin accumulation and lactic acidosis.
• Lung - Contraindicated in patients with symptomatic heart failure (NYHA Class III or IV) due to the pioglitazone component, which can cause fluid retention and exacerbate lung congestion.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.